```text
1. Verdict: REVISE_BEFORE_USER_REVIEW

2. Top Socratic Questions:

Q1. What is the concrete artifact the CTO opens? The spec says "open one evidence packet" but never defines its shape for a buyer. If it's raw Markdown or JSON, no C-level buyer buys that. Is it a rendered HTML report, a PR-commentable summary, a CLI one-liner, or a static PDF export? The first wedge is the format, not the ontology.

Q2. How does "GitHub-first" work when a Russian enterprise buyer is actively migrating away from GitHub due to sanctions risk? If GitFlic is named as a future adapter but the entire evidence packet language, examples, and P0 slices assume GitHub, the first 6 months of product work are unusable for your own stated adoption market. Should Slice P0-B be "GitHub AND GitFlic change-host model" instead of GitHub-only?

Q3. What compliance or audit framework does your evidence packet map to? A Russian enterprise CTO does not buy "honest work." They buy FSTEC, ISO 27001, SOC 2-type readiness, or at least a story they can tell their security department. The evidence theater taxonomy is excellent engineering, but it is not a compliance narrative. How does `not_assessed` on row 17 translate to an audit finding?

Q4. Which evidence packet row would cause a buyer to cancel a pilot? If "most rows are `not_assessed` in early adopter phase" is the honest answer, how do you prevent the product from looking like it produces nothing? What is the minimum viable `pass` density that makes the first packet useful rather than discouraging?

Q5. Who pays for the first pilot, and what procurement path exists? sdp-trace is OSS-licensed, no dashboard, no SaaS. Does the buyer pay for integration services, support, or an enterprise license? If the answer is "we don't know yet," the roadmap has no commercial wedge.

Q6. What prevents a CTO from saying "I can get 80% of this from GitHub Advanced Security + my SIEM"? Where is sdp-trace's differentiation boundary versus existing enterprise tooling? The spec answers this for engineers but not for a CTO comparing budgets.

Q7. Are the P0 priorities aligned with CTO pain or with OSS developer availability? OpenCode+GSD and pi/GSD2 discovery are P0, but those are developer tooling concerns. A C-level buyer may care more about "which agent touched our prod deploy last Tuesday" before they care about OpenCode JSONL normalization. Should the CTO evidence packet (User Story 1) move ahead of tool-chain discovery as the actual first delivery?

Q8. If a customer uses a private Git host with no API, no CI, and no agent session export, what does sdp-trace produce? If the answer is "nothing" or "only manual input," is that honest enough to put in the first buyer conversation?

3. Findings Table:

| id | severity | cited file:line | finding | why it matters | exact fix |
|---|---|---|---|---|---|
| F-01 | critical | spec.md:55-67 | User Story 1 describes the CTO packet but never defines its output format, length, or reading surface. | A CTO cannot evaluate a value proposition that has no concrete artifact. Without format, there is no wow, no demo, no first impression. | Add a concrete packet shape: one-page summary format, field-by-field example, and reading time estimate. Include one mocked CTO packet in examples/ before User Review. |
| F-02 | critical | spec.md:43-51 | "Out of scope" includes GitHub dependency, but P0-A through P0-C assume GitHub evidence is available. Russian enterprises may have zero GitHub access. | The product's first adopter market cannot use the first three P0 slices if they have migrated off GitHub. | Add parallel P0-B' for GitFlic or define a provider-neutral packet that works with zero change-host API, using only local Git + CI artifacts. |
| F-03 | major | spec.md:192-211 | Evidence theater taxonomy is eight categories but mapped to zero compliance or audit frameworks. | Enterprise buyers need to translate theater findings into audit language. Without this mapping, the taxonomy is internal-only. | Add one row per theater category showing its equivalent audit risk (e.g., "actor laundering" -> access control / identity mapping gap). |
| F-04 | major | spec.md:215-249 | FR-001 through FR-015 describe evidence semantics but contain zero ROI, time-saved, or risk-reduction metrics. | C-level buyers buy outcomes, not ontologies. Without measurable value, the product collapses into an engineering curiosity. | Add one functional requirement that states the measurable reduction in investigation time or unbacked-claim rate the packet must produce. |
| F-05 | major | plan.md:96-101 | Slice P0-A exit criteria say "one sample packet maps a PR to facts" but no mock exists and no format is committed. | Exit criteria are unverifiable until the packet shape is concrete enough to review. | Commit a markdown or HTML sample CTO packet with real or redacted data before requesting user approval. |
| F-06 | major | research.md:107-131 | Integration notes name GitHub, OpenCode, pi, GSD, GSD2, Superpowers but contain zero Russian-market tools (GitFlic API, domestic CI, local attestation systems). | Russian enterprise adoption requires at least discovery notes for local integration targets even if they are P1+. | Add a discovery row for GitFlic change-host surface and one domestic CI or artifact system (e.g., TeamCity, GitLab self-hosted) before claiming enterprise readiness. |
| F-07 | minor | spec.md:29-35 | Scope names OpenCode, GSD, GSD2, Superpowers as in-scope tools, giving each individual names. | Naming creates implicit support expectations. FR-013 says every named tool needs evidence surface inspection, but this is not visible in the scope section itself. | Add an "(evidence surface not yet inspected)" tag next to each named tool in Scope, or move them to a "Discovery Targets" sub-section. |
| F-08 | minor | tasks.md:9-22 | Phase 0 has T005-T007 as "run review, resolve findings, stop for approval" but T001-T004 are already checked. | The review is happening right now, but tasks.md implies the review is not started. This is a bookkeeping mismatch. | Mark T005 as in-progress; do not check it until the review disposition is recorded. |
| F-09 | major | spec.md:168-191 | User Story 5 (Signed Attestation) is P2, but no migration path from "local evidence packet" to "signed enterprise packet" is described. | Enterprise procurement may require signed evidence on day one for certain workload classes. If P2 is the only path, early enterprise adoption is blocked. | Add a note in research.md describing the minimum evidence fields that would satisfy a typical enterprise procurement security review, even without full signing. |
| F-10 | minor | plan.md:178-202 | Review gates are defined but contain no C-level readability gate or buyer demo gate. | The gates are engineering quality gates. A CTO buyer gate should exist before implementation scope approval. | Add a "buyer readability review" gate: one non-engineer reads the packet and can identify agent route, evidence, gaps, and owner in under 2 minutes. |

4. Missing Evidence / `not_assessed` Areas:

- **CTO packet format**: Never defined. Entire buyer value proposition rests on an undefined artifact.
- **Russian market integration surface**: GitFlic API, domestic CI, local CA/PKI for signed attestation equivalents, FSTEC/FSB compliance mapping.
- **Procurement path**: OSS license type, commercial model, support SLA, data residency requirements.
- **Competitive differentiation**: GitHub Advanced Security, Snyk, Dependency-Track, in-toto, Sigstore, existing SBOM tooling. Why sdp-trace vs. these?
- **Minimum viable evidence density**: What ratio of `pass` vs `not_assessed` makes the first packet useful enough to adopt?
- **Non-API change hosts**: What does sdp-trace produce when there is no GitHub, no GitLab, no CI API - only local Git and maybe a Jenkins artifact tarball?

5. Scope-Control Risks:

- **Tool sprawl through naming**: spec.md names 8+ specific tools in scope. Each creates an implicit "support claimed" expectation even with FR-013 safeguards. CTOs will ask "do you support X?" before evidence is ready.
- **GitHub anchoring**: 3 of 7 roadmap slices assume GitHub evidence availability. If Russian enterprises cannot use GitHub, 43% of the roadmap is wasted for that market.
- **Harness-as-intent vs. harness-as-fact boundary is fragile**: GSD declares a phase; is compliance claimed? The spec says "intent only unless separately verified." But who verifies? If no one verifies, most rows are `not_assessed` and buyers lose confidence.
- **Signed attestation as P2 may block enterprise adoption**: If a buyer's procurement requires signed change records, P0/P1 packets cannot close the deal.

6. One Strongest Reason to Proceed:

The evidence theater taxonomy is genuinely novel and addresses a blind spot that existing tools (GitHub, SIEM, SBOM, Sigstore) do not cover. No current product says "this claim was made by an agent, witnessed by CI, but unverified by review, and here is the missing binding to the original intent." That narrative is a real C-level worry, and sdp-trace is the only thing positioned to answer it with evidence, not marketing.

7. One Strongest Reason Not to Proceed Yet:

There is no concrete buyer artifact. The roadmap describes ontology, evidence semantics, integration slices, and task decomposition, but the CTO never sees the actual packet. Without a mock packet that a C-level reader can evaluate in under two minutes, there is no product wedge to sell, no demo to show, and no reason for a buyer to care about evidence semantics. Build the packet shape first; then the rest of the roadmap follows.
```
